Global Trends in the Epidemiology and Management of Dyslipidemia
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Dyslipidemia, especially a circulating non-optimal level of cholesterol, is one of the most important risk factors for atherosclerotic cardiovascular disease (ASCVD), which accounts for the most deaths worldwide. Maintaining a healthy level of blood cholesterol is an important prevention strategy for ASCVD, through lifestyle intervention or cholesterol-lowering therapy. Over the past three decades, the epidemiology and management of dyslipidemia has changed greatly in many countries. Therefore, it is necessary to understand the current epidemiologic features of dyslipidemia and challenges from a global perspective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.003 · Cited by 2,691
Borén, J., Chapman, M. J., Krauss, R. M., Packard, C. J., Bentzon, J. F., Binder, C. J., Daemen, M. J., Demer, L. L., Hegele, R. A., Nicholls, S. J., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz962 · Cited by 1,601
Anderson, T. J., Grégoire, J., Pearson, G. J., Barry, A. R., Couture, P., Dawes, M., Francis, G. A., Genest, J., Grover, S., Gupta, M., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.07.510 · Cited by 1,173
Global epidemiology of dyslipidaemias
Pirillo, A., Casula, M., Olmastroni, E., Norata, G. D., & Catapano, A. L. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00541-4 · Cited by 882
Kinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., Umemoto, S., Egusa, G., Ohmura, H., Okamura, T., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2017 · Cited by 813
Sandesara, P. B., Virani, S. S., Fazio, S., & Shapiro, M. D. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00184 · Cited by 608 · cited 1×
“Circulating non-optimal cholesterol, including increased low-density lipoprotein cholesterol (LDL-C) and remnant cholesterol carried by triglyceride-rich lipoproteins, comprises the main type of dyslipidemia worldwide and is a major risk factor for atherosclerotic cardiovascular disease (ASCVD) [1].”
BackgroundRemnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: A primary prevention study
Quispe, R., Martin, S. S., Michos, E. D., Lamba, I., Blumenthal, R. S., Saeed, A., Lima, J., Puri, R., Nomura, S., Tsai, M., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab432 · Cited by 441
Salami, J. A., Warraich, H., Valero-Elizondo, J., Spatz, E. S., Desai, N. R., Rana, J. S., Virani, S. S., Blankstein, R., Khera, A., Blaha, M. J., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2016.4700 · Cited by 370
Marston, N. A., Giugliano, R. P., Im, K., Silverman, M. G., O’Donoghue, M. L., Wiviott, S. D., Ference, B. A., & Sabatine, M. S. (2019) · Circulation · doi:10.1161/circulationaha.119.041998 · Cited by 301 · cited 1×
“Fibrates are recommended to lower triglyceride levels [21,23–25,27–30,34], but there are still no trials to show the cardiovascular benefit of fibrates except for meta-analysis of high triglyceride and low HDL-C groups [36], and recently the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Pa…”
BackgroundKhan, S. U., Yedlapati, S. H., Lone, A. N., Hao, Q., Guyatt, G., Delvaux, N., Bekkering, G. E. (., Vandvik, P. O., Riaz, I. B., Li, S., et al. (2022) · BMJ · doi:10.1136/bmj-2021-069116 · Cited by 151 · cited 1×
“There is considerable evidence supporting the benefits of nonstatin cholesterol-lowering medications in combination with statins, especially cholesterol absorption inhibitors (ezetimibe) and PCSK9 inhibitors [45,46].”
BackgroundMcConnachie, A., Walker, A., Robertson, M., Marchbank, L., Peacock, J., Packard, C. J., Cobbe, S. M., & Ford, I. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht232 · Cited by 104
Lee, Z.-V., Llanes, E. J., Sukmawan, R., Thongtang, N., Ho, H. Q. T., Barter, P., & on behalf of the Cardiovascular RISk Prevention (CRISP) in Asia Network (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01450-8 · Cited by 41
Research works printed but not linked: 31
- Chen, 2021, Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis, Nat. Rev. Cardiol., 19, 228, 10.1038/s41569-021-00629-x · DOI · Paper page
- Almahmeed, 2016, Dyslipidaemia in the Middle East: Current status and a call for action, Atherosclerosis, 252, 182, 10.1016/j.atherosclerosis.2016.07.925 · DOI
- NCD Risk Factor Collaboration (2020). Repositioning of the global epicentre of non-optimal cholesterol. Nature, 582, 73–77. · DOI · Paper page
- Hoffmann, 2018, A large electronic-health-record-based genome-wide study of serum lipids, Nat. Genet., 50, 401, 10.1038/s41588-018-0064-5 · DOI · Paper page
- Mortensen, M.B., Falk, E., and Schmidt, M. (2017). Twenty-Year Nationwide Trends in Statin Utilization and Expenditure in Denmark. Circ. Cardiovasc. Qual. Outcomes, 10. · DOI · Paper page
- Vancheri, 2016, Time trends in statin utilisation and coronary mortality in Western European countries, BMJ Open, 6, e010500, 10.1136/bmjopen-2015-010500 · DOI · Paper page
- Zhu, 2018, 2016 Chinese guidelines for the management of dyslipidemia in adults, J. Geriatr. Cardiol., 15, 1
- Oliva, 2021, Executive Summary of the 2020 Clinical Practice Guidelines for the Management of Dyslipidemia in the Philippines, J. ASEAN Fed. Endocr. Soc., 36, 5, 10.15605/jafes.036.01.01 · DOI
- Malaysia Ministry of Health (2022, July 01). Management of Dyslipidaemia 2017 5th Edition. Available online: http://www.acadmed.org.my/index.cfm?&menuid=67.
- Iyengar, 2016, Lipid Association of India Expert Consensus Statement on Management of Dyslipidemia in Indians 2016: Part 1, J. Assoc. Physicians India, 64, 7
- Rhee, 2019, 2018 Guidelines for the Management of Dyslipidemia in Korea, J. Lipid Atheroscler., 8, 78, 10.12997/jla.2019.8.2.78 · DOI · Paper page
- Banach, 2021, PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021, Arch. Med. Sci., 17, 1447, 10.5114/aoms/141941 · DOI
- Jellinger, 2017, American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease-Executive Summarycomplete Appendix to Guidelines, Endocr. Pract., 23, 479, 10.4158/EP171764.GL · DOI · Paper page
- Klug, 2018, South African dyslipidaemia guideline consensus statement: 2018 update A joint statement from the South African Heart Association (SA Heart) and the Lipid and Atherosclerosis Society of Southern Africa (LASSA), S. Afr. Med. J., 108, 973, 10.7196/SAMJ.2018.v108i11.13383 · DOI
- Yokoyama, 2007, Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis, Lancet, 369, 1090, 10.1016/S0140-6736(07)60527-3 · DOI · Paper page
- Hai, Q., and Smith, J.D. (2021). Acyl-Coenzyme A: Cholesterol Acyltransferase (ACAT) in Cholesterol Metabolism: From Its Discovery to Clinical Trials and the Genomics Era. Metabolites, 11. · DOI
- Zhao, 2015, Cardiovascular risk assessment: A global perspective, Nat. Rev. Cardiol., 12, 301, 10.1038/nrcardio.2015.28 · DOI
- Yebyo, H.G., Zappacosta, S., Aschmann, H.E., Haile, S.R., and Puhan, M.A. (2020). Global variation of risk thresholds for initiating statins for primary prevention of cardiovascular disease: A benefit-harm balance modelling study. BMC Cardiovasc. Disord., 20. · DOI
- Lu, Y., Wang, P., Zhou, T., Lu, J., Spatz, E.S., Nasir, K., Jiang, L., and Krumholz, H.M. (2018). Comparison of Prevalence, Awareness, Treatment, and Control of Cardiovascular Risk Factors in China and the United States. J. Am. Heart Assoc., 7. · DOI · Paper page
- Kim, 2022, Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): A randomised, open-label, non-inferiority trial, Lancet, 400, 380, 10.1016/S0140-6736(22)00916-3 · DOI · Paper page
- Salami, 2018, National Trends in Nonstatin Use and Expenditures among the US Adult Population From 2002 to 2013: Insights from Medical Expenditure Panel Survey, J. Am. Heart Assoc., 7, e007132, 10.1161/JAHA.117.007132 · DOI · Paper page
- Zhang, 2018, Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults: A nationally representative survey of 163,641 adults, Int. J. Cardiol., 260, 196, 10.1016/j.ijcard.2017.12.069 · DOI · Paper page
- Li, 2015, ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): A retrospective analysis of hospital data, Lancet, 385, 441, 10.1016/S0140-6736(14)60921-1 · DOI · Paper page
- Xing, 2019, Prehospital statin use and low-density lipoprotein cholesterol levels at admission in acute coronary syndrome patients with history of myocardial infarction or revascularization: Findings from the Improving Care for Cardiovascular Disease in China (CCC) project, Am. Heart J., 212, 120, 10.1016/j.ahj.2019.02.019 · DOI
- Lu, 2021, Prevalence of Dyslipidemia and Availability of Lipid-Lowering Medications Among Primary Health Care Settings in China, JAMA Netw. Open, 4, e2127573, 10.1001/jamanetworkopen.2021.27573 · DOI · Paper page
- Lazar, 2011, Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era, Circulation, 124, 146, 10.1161/CIRCULATIONAHA.110.986349 · DOI · Paper page
- Heller, 2017, Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke, Circulation, 136, 1087, 10.1161/CIRCULATIONAHA.117.027067 · DOI · Paper page
- Wang, 2020, Impact of China’s Low Centralized Medicine Procurement Prices on the Cost-Effectiveness of Statins for the Primary Prevention of Atherosclerotic Cardiovascular Disease, Glob. Heart, 15, 43, 10.5334/gh.830 · DOI
- Yang, 2020, Cost-Effectiveness Analysis of Ezetimibe as the Add-on Treatment to Moderate-Dose Rosuvastatin versus High-Dose Rosuvastatin in the Secondary Prevention of Cardiovascular Diseases in China: A Markov Model Analysis, Drug Des. Dev. Ther., 14, 157, 10.2147/DDDT.S213968 · DOI
- Pan, 2016, The prevalence, awareness, treatment and control of dyslipidemia among adults in China, Atherosclerosis, 248, 2, 10.1016/j.atherosclerosis.2016.02.006 · DOI · Paper page
- Writing Committee, Lloyd-Jones, D.M., Morris, P.B., Ballantyne, C.M., Birtcher, K.K., Covington, A.M., DePalma, S.M., Minissian, M.B., Orringer, C.E., and Smith, S.C. (2022). 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J. Am. Coll. Cardiol., 80, 1366–1418. · DOI · Paper page
Cited by
Zou, D., Hu, Q., Liu, Y., & Yu, L. (2024) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-024-01784-0 · Cited by 5
“Current cholesterol-lowering medications mainly include statins, cho-lesterol-absorption inhibitors, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors [2].”
Cinza-Sanjurjo, S., Barrios, V., Fierro-González, D., Polo-García, J., & Pallarés-Carratalá, V. (2024) · Cardiovascular Therapeutics · doi:10.1155/2024/4227941 · Cited by 4
“Compared with the DA VINCI study, developed immediately after the publication of the current recommended goals, our results obtained four years after its publication shows that there is an increase in the use of intensive therapies, as in neighboring countries [20, 21].”
Metadata
- Authors
- Liu, T., Zhao, D., & Qi, Y.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2022-10-28
- Volume
- 11
- Issue
- 21
- Pages
- 6377
- ISSN
- 2077-0383
- Cited by
- 62
- References
- 20
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.